 |
|
|
February 7, 2011
| Torii Pharmaceutical Co., Ltd. |
|
|
| Torii Pharmaceutical to Launch Hyperkalemia Improvement Agent, KAYEXALATE® DRYSYRUP 76% |
|
Torii Pharmaceutical Co., Ltd. announced today that the company launched a hyperkalemia improvement agent, "KAYEXALATE® DRYSYRUP 76% (generic name: sodium polystyrene sulfonate)".
"KAYEXALATE®" is a hyperkalemia improvement agent whose active ingredient is sodium polystyrene sulfonate. It improves hyperkalemia by exchanging potassium ions in the intestinal tract. "KAYEXALATE® DRYSYRUP 76%" is a low-calorie preparation featuring a refreshing apple flavor, developed as a new dosage form of "KAYEXALATE® POWDER". It is expected to broaden the range of options for potassium-lowering agents, and to contribute to enhancing the patientsÂ’ quality of life.
An outline of "KAYEXALATE® DRYSYRUP 76%" is shown below.
| |
|
| Product outline of KAYEXALATE® DRYSYRUP 76% |
|
|
|
1. Brand name: |
KAYEXALATE® DRYSYRUP 76% |
|
2. Generic name: |
Sodium polystyrene sulfonate |
|
3. Indication: |
Hyperkalemia caused by acute and chronic renal failure |
|
4. Dosage and administration: |
The usual oral dosage for adults is 39.24 g per day (30 g per day as sodium polystyrene sulfonate) divided into 2-3 doses. A single dose is suspended in 50-150 ml
of water, and administered orally. The dosage may be adjusted according to symptoms. |
|
5. Date of manufacturing and marketing approval: |
July 15, 2010 |
|
6. Date of NHI price listing: |
November 19, 2010 |
|
7. Packaging: |
3.27g x 84 packs (2 packs Ă— 42) |
|
8. NHI (reimbursement) price: |
¥20.00/g |
|
9. Distributed by: |
Torii Pharmaceutical Co., Ltd. |
|
|
|
|
|
| |
|
|
|
|
